AptarGroup, Inc.

NYSE:ATR Stock Report

Market Cap: US$7.8b

AptarGroup Future Growth

Future criteria checks 1/6

AptarGroup is forecast to grow earnings and revenue by 6.8% and 5.5% per annum respectively. EPS is expected to grow by 6.7% per annum. Return on equity is forecast to be 12.6% in 3 years.

Key information

6.8%

Earnings growth rate

6.75%

EPS growth rate

Packaging earnings growth19.3%
Revenue growth rate5.5%
Future return on equity12.60%
Analyst coverage

Good

Last updated21 Apr 2026

Recent future growth updates

Recent updates

ATR: Nasal Therapies And Share Buybacks Will Support Future Upside

Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.

ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside

Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).

ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside

Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.

ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio

Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.

ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential

Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.

ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns

Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.

ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook

AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).

ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns

Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).

ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns

Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.

We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)

Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)

ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential

Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.

ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside

Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).

ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside

Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).

AptarGroup: Pharma Setback Creates Long-Term Opportunities

Nov 02

ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions

Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.

AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48

Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48

Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare

The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.

AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't

Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't

AptarGroup's (NYSE:ATR) Dividend Will Be $0.45

Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45

Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?

Jul 02
Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?

These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well

Jun 19
These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well

AptarGroup's (NYSE:ATR) Returns Have Hit A Wall

May 13
AptarGroup's (NYSE:ATR) Returns Have Hit A Wall

AptarGroup Has Gotten Too Expensive

Dec 02
User avatar

Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge

Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.

Earnings and Revenue Growth Forecasts

NYSE:ATR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20284,397438452N/A3
12/31/20274,1324084527558
12/31/20263,9373514026828
12/31/20253,777393295570N/A
9/30/20253,663419306565N/A
6/30/20253,611392342616N/A
3/31/20253,555370356634N/A
12/31/20243,583375349643N/A
9/30/20243,573336378685N/A
6/30/20243,557320323629N/A
3/31/20243,543313254569N/A
12/31/20233,487284257575N/A
9/30/20233,445281209528N/A
6/30/20233,389251159484N/A
3/31/20233,337232164485N/A
12/31/20223,322239163479N/A
9/30/20223,34023888410N/A
6/30/20223,32923146365N/A
3/31/20223,29522366383N/A
12/31/20213,22724456363N/A
9/30/20213,163240156448N/A
6/30/20213,096256256518N/A
3/31/20212,985243307557N/A
12/31/20202,929214318570N/A
9/30/20202,851209283516N/A
6/30/20202,793202273521N/A
3/31/20202,837234261522N/A
12/31/20192,860242267514N/A
9/30/20192,873234N/A484N/A
6/30/20192,838217N/A380N/A
3/31/20192,806198N/A340N/A
12/31/20182,765195N/A314N/A
9/30/20182,706204N/A269N/A
6/30/20182,664218N/A330N/A
3/31/20182,571228N/A338N/A
12/31/20172,469220N/A325N/A
9/30/20172,382220N/A388N/A
6/30/20172,348220N/A390N/A
3/31/20172,350214N/A352N/A
12/31/20162,331206N/A325N/A
9/30/20162,339199N/A296N/A
6/30/20162,335200N/A269N/A
3/31/20162,310198N/A297N/A
12/31/20152,317199N/A324N/A
9/30/20152,370198N/A346N/A
6/30/20152,435193N/A346N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATR's forecast earnings growth (6.8% per year) is above the savings rate (3.4%).

Earnings vs Market: ATR's earnings (6.8% per year) are forecast to grow slower than the US market (16.1% per year).

High Growth Earnings: ATR's earnings are forecast to grow, but not significantly.

Revenue vs Market: ATR's revenue (5.5% per year) is forecast to grow slower than the US market (11% per year).

High Growth Revenue: ATR's revenue (5.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ATR's Return on Equity is forecast to be low in 3 years time (12.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/30 06:11
End of Day Share Price 2026/04/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AptarGroup, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ghansham PanjabiBaird
Mark WildeBMO Capital Markets Equity Research
George StaphosBofA Global Research